On the structural basis of the hypertensive properties of angiotensin II: A solved mystery or a controversial issue?

Current Topics in Medicinal Chemistry

Volumn 4, Issue 4, 2004, Pages 431-444

  Tzakos, Andreas G ^a   Gerothanassis, Ioannis P ^a   Troganis, Anastassios N ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; CANDESARTAN; EPROSARTAN; IRBESARTAN; LIGAND; LOSARTAN; MONOCLONAL ANTIBODY; PEPTIDE HORMONE; SOLVENT; TELMISARTAN; VALSARTAN; VASOCONSTRICTOR AGENT;

AQUEOUS SOLUTION; CONFORMATION; DIELECTRIC CONSTANT; DRUG STRUCTURE; HORMONE ACTION; HORMONE STRUCTURE; HUMAN; HYPERTENSION; MOLECULAR MIMICRY; PATHOPHYSIOLOGY; PHARMACOPHORE; PROTEIN TARGETING; RECEPTOR BINDING; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIMULATION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANGIOTENSIN II; HUMANS; HYPERTENSION; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; VASOCONSTRICTOR AGENTS;

EID: 3042850174     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043451375     Document Type: Review

References (150)

1. Samanen, J.; Regoli, D. Structure - Activity Relationships of Peptide Angiotensin II Receptor Agonists and Antagonists. In Ruffdo R.R. (Ed.) Angiotensin II Receptors. CRC Press: Boca Raton, FL, Vol 2, 1994; pp 11-97.
2. Campbell, D. J. Circulating and Tissue Angiotensin Systems. J. Clin. Invest. 1987, 79, 1-6.
3. Dzau, V. J.; Kristin, E. E.; Brody, T.; Ingelfinger, J.; Pratt, R. E. A Comparative Study of the Distributions of Renin and Angiotensinogen Messenger Ribonucleic Acids in Rat and in Mouse and in Rat Tissues. Endocrinology, 1987, 120, 2334-2338.
4. Culman, J.; Baulmann, J.; Blume, A.; Unger, T. The Renin-Angiotensin System in the Brain: an Update. J. Renin Angiotensin Aldosterone Syst. 2001, 2, 96-102.
5. Dinh, D. T.; Frauman, A. G.; Sourial, M.; Casley, D. J.; Johnston, C. I.; Fabiani, M. E. Identification, Distribution, and Expression of Angiotensin II Receptors In the Normal Human Prostate and Benign Prostatic Hyperplasia. Endocrinology 2001, 142, 1349-1356.
6. Li, Q.; Pfaffendorf, M.; van Zwieten, P. A. Different Types of Antagonism by Losartan and Irbesartan on the Effects of Angiotensin II and its Degradation Products in Rabbit Arteries. Fundam. Clin. Pharmacol. 2001, 15, 143-150.
7. Greenland, K.; Wyse, B.; Sernia, C. Identification and Characterization of Angiotensin IV Binding Sites in Rat Neurone and Astrocyte Cell Cultures. J. Neuroendocrinol. 2001, 8, 687-693.
8. Reaux, A.; Fournie-Zaluski, M. C.; Llorens-Cortes, C. Angiotensin III: A Central Regulator of Vasopressin Release and Blood Pressure. Trends Endocrinol. Metab. 2001, 12, 157-162.
9. De Gasparo, M.; Catt, K. J.; Inagami, T.; Wright, J. W.; Unger, T. International Union of Pharmacology. XXIII. The Angiotensin II Receptors. Pharmacol. Rev. 2000, 52, 415-472.
10. Lucius, R.; Gallinat, S.; Busche, S.; Rosenstiel, P.; Unger, T. Beyond Blood Pressure: New Roles for Angiotensin II. Cellular and Molecular Life Sciences 1999, 56, 1008-1019.
11. Matsusaka, T.; Miyazaki, Y.; Ichikawa, I. The Renin Angiotensin System and Kidney Development. Annu. Rev. Physiol. 2002, 64, 551-561.
12. Leung, P. S.; Carlsson, P. O. Tissue Renin-Angiotensin System: Its Expression, Localization, Regulation and Potential Role in the Pancreas. J. Mol. Endocrinol. 2001, 26, 155-64.
13. Greene, A. S.; Amaral, S. L. Microvascular Angiogenesis and the Renin-Angiotensin System. Curr. Hypertens. Rep. 2002, 4, 56-62.
14. Blume, A.; Herdegen, T.; Unger, T. Angiotensin Peptides and Inducible Transcription Factors. J. Mol. Med. 1999, 77, 339-357.
15. Lapointe, N.; Rouleau, J. L. Cardioprotective Effects of Vasopeptidase Inhibitors. Can. J. Cardiol. 2002, 18, 415-420.
16. Sperling, R. L. ACE Inhibitors. Home Healthe. Nurse. 2001, 19, 47-49.
17. Guo, D. F.; Sun, Y. L.; Hamet, P.; Inagami, T. The Angiotensin II Type 1 Receptor and Receptor-Associated Proteins, Cell. Res. 2001, 11, 165-180.
18. Ardaillou, R. Angiotensin II Receptors. J. Am. Soc. Nephrol. 1999, 10, Suppl. 11, S30-39.
19. Dampney, R. A.; Fontes, M. A.; Hirooka, Y.; Horiuchi, J.; Potts, P. D.; Tagawa, T. Role of Angiotensin II Receptors in the Regulation of Vasomotor Neurons in the Ventrolateral Medulla. Clin. Exp. Pharmacol. Physiol. 2002, 29, 467-472.
20. Timmermans, P. B.; Wong, P. C.; Chiu, A. T.; Herblin, W. F.; Benfield, P.; Carini, D. J.; Lee, R., J.; Wexler, R. R.; Saye, J. A.; Smith, R. D. Angiotensin II Receptors and Angiotensin II Receptor Antagonists. Pharmacol. Rev. 1993, 45, 205-251.
21. Morsing, P.; Vauquelin, G. How Can the Differences Among AT1-Receptor Antagonists Be Explained? Cell. Biochem. Biophys. 2001, 35, 89-102.
22. Coats, A. J. Angiotensin Type-1 Receptor Blockers in Heart Failure. Prog. Cardiovasc. Dis. 2002, 44, 231-242.
23. Burnier, M.; Brunner, H. R. Angiotensin II Receptor Antagonists. Lancet 2000, 355, 637-645.
24. Kurup, A.; Garg, R.; Carini, D. J.; Hansch, C. Comparative QSAR: Angiotensin II Antagonists. Chem. Rev. 2001, 101, 2727-2750.
25. Ondetti, M. A.; Cushman, D. W. Inhibition of the Renin-Angiotensin System. A New Approach to the Therapy of Hypertension. J. Med. Chem. 1981, 24, 355-361.
26. 5-Angiotensin II. Biochim. Biophys. Acta. 1962, 58, 550-557.
27. Scanlon, M. N.; Matsoukas, J. M.; Franklin, K. J.; Moore, G. J. A New Approach to Angiotensin Antagonists: Methylation of the Tyrosine Hydroxyl in Angiotensin II. Life Sci. 1984, 34, 317-321.
28. Andreatta, R.; Hofmann, K. Studies on Polypeptides. XLI. The Synthesis of [5-valine, 6-beta-(pyrazolyl-3)-alanine]-Angiotensin II, a Potent Hypertensive Peptide. J. Am. Chem. Soc. 1968, 90, 7334-7338.
29. Turker, R. K.; Hall, M. M.; Yamamoto, M.; Sweet, C. S.; Bumpus, F. M. A New, Long-Lasting Competitive Inhibitor of Angiotensin. Science 1972, 177, 1203-1205.;
30. Hodges, J. C.; Hamby J. M.; Blankley, C. J. Angiotensin II Receptor Binding Inhibitors. Drugs. Future. 1992, 17, 575-593.
31. 1 Angiotensin Receptor is Generated by Angiotensin II Induction. Biochemistry 1996, 35, 16435-16442.
32. Khosla, M. C.; Hall, M. M.; Smeby, R. R.; Bumpus, F. M. Factors that Influence the Antagonistic Properties of Angiotensin II Antagonists. J. Med. Chem. 1973, 16, 829-832.
33. Chaturvedi, N. C.; Park, W. K.; Smeby, R. R.; Bumpus, F. M. Analogs of Angiotensin II. I. Solid Phase Synthesis. J. Med. Chem. 1970, 13, 177-181.
34. Matsoukas, J. M., Goghari, M. H., Scanlon, M. N., Franklin, K. J.; Moore, G. J. Synthesis and Biological Activities of Analogues of Angiotensins II and III Containing O-Methyltyrosine and D-Tryptophan. J. Med. Chem. 1985, 28, 780-783.
35. Matsoukas, J. M.; Agelis, G.; Wahhab, A.; Hondrelis, J.; Panagiotopoulos, D.;Yamdagni, R.; Wu, Q.; Mavromoustakos, T.; Maia, H. L.; Ganter, R.; Moore, G. Differences in Backbone Structure Between Angiotensin II Agonists and Type I Antagonists. J. Med. Chem. 1995, 38, 4660-4669.
36. Regoli, D.; Rioux, F.; Park, W. K.; Choi, C. Role of the N-Terminal Amino Acid for the Biological Activities of Angiotensin and Inhibitory Analogues. Can J. Physiol. Pharmacol. 1974, 52, 39-49.
37. Hall, M. M.; Khosla, M. C.; Khairallah, P. A.; Bumpus, F. M. Angiotensin Analogs: The Influence of Sarcosine Substituted in Position 1. J. Pharmacol. Exp. Ther. 1974, 188, 222-8.
38. Ganter, R. C.; Goghari, M. H.; Moore, G. J. The Contribution of the N-Terminal Region of Angiotensin II Antagonists to Receptor Binding. Proc. West. Pharmacol. Soc. 1987, 30, 113-6.
39. 1 Receptor is Essential for Full Agonism. J. Biol. Chem. 1995, 270, 12846-12850.
40. Hondrelis, J.; Matsoukas, J.; Cordopatis, P.; Ganter, R. C.; Franklin, K. J.; Moore, G. J. Synthesis and Biological Activities of Angiotensin II and Sarmesin Analogues Containing Cyclohexylalanine. Int. J. Pept. Protein. Res. 1991, 37, 21-26.
41. 4] Angiotensin II (Sarmesin). J. Med. Chem. 1986, 29, 1121-1124.
42. Needleman, P.; Marshall, G. R.; Rivier, J. Angiotensin II. Synthesis and Biological Activity of 6-(1-methylhistidine) and 6-(3-methylhistidine) Analogs. J. Med. Chem. 1973, 16, 968-970.
43. Jorgensen, W. Rusting of the Lock and Key Model for Protein-Ligand Binding. Science 1991, 254, 954-955.
44. Craig, L. C. Conformation Studies with Polypeptides by Rotatory Dispersion and Thin-Film Dialysis. Proc. Natl. Acad. Sci. U S A 1968, 61, 152-159.
45. Surewicz, W. K.; Mantsch, H. H. Conformational Properties of Angiotensin-II in Aqueous-Solution and in a Lipid Environment - A Fourier-Transform Infrared Spectroscopic Investigation. J. Am. Chem. Soc. 1988, 110, 4412-4414.
46. 5]-Angiotensin II. Can. J. Biochem. 1977, 55, 75-82.
47. 7 -Angiotensin III by Fluorescence Measurements. Can. J. Biochem. 1979, 57, 402-407.
48. Schiller, P. W. Determination of the Average End-to-End Distance of Two Angiotensin II Analogs by Resonance Energy Transfer. Int. J. Pept. Protein. Res. 1980, 16, 259-266.
49. 15) in Aqueous Solution. Biochemistry 1973, 12, 3684-3692;
50. 15) in Aqueous Solution Employing Correlation Spectroscopy. Assignment of Peptide NH Resonances and Transfer of Saturation from Water. Biochemistry 1974, 13, 11-14.
51. Cushman, J. A.; Mishra, P. K.; Bothner-By, A. A.; Khosla, M. S. Conformations in Solution of Angiotensin II, and its 1-7 and 1-6 Fragments. Biopolymers 1992, 32, 1163-1171.
52. Printz, M. P.; Nemethy, G.; Bleich, H. Proposed Models for Angiotensin II in Aqueous Solution and Conclusions About Receptor Topography. Nat. New Biol. 1972, 237, 135-140.
53. Printz, M. P.; Williams, H. P.; Craig, L. C. Evidence for the Presence of Hydrogen-Bonded Secondary Structure in Angiotensin II in Aqueous Solution. Proc. Natl. Acad. Sci. U. S. A. 1972, 69, 378-382.
54. Marshall, G. R.; Bosshard, H. E.; Vine, W. H.; Glickson, J. D. NMR Evidence Against Gamma Turn and Beta Turn Models of Angiotensin II in Aqueous Solution. Nat. New Biol. 1973, 245, 125-127.
55. Fermandjian, S.; Fromageot, P.; Tistchenko, A. M.; Leicknam, J. P.; Lutz, M. Angiotensin II Conformations. Infrared and Raman Studies. Eur. J. Biochem. 1972, 28, 174-182.
56. 5 Structure. Application to Angiotensin II. Int. J. Pept. Protein. Res. 1984, 24, 543-552.
57. 5]Angiotensin II, Angiotensin III and Saralasin. Biochim. Biophys. Acta 1981, 667, 157-167.
58. Lenkinski, R. E.; Stephens, R. L.; Krishna, N. R. Conformation of Angiotensin II. Evidence for a Specific Hydrogen Bonded Conformation. Biochemistry 1981, 20, 3122-3126.
59. 1H Nuclear Magnetic Resonance. Proc. Natl. Acad. Sci. U S A 1980, 77, 82-86.
60. Weinkam, R. J.; Jorgensen, E. C. Angiotensin II Analogs. VIII. The Use of Free Radical Containing Peptides to Indicate the Conformation of the Carboxyl Terminal Region of Angiotensin II. J. Am. Chem. Soc. 1971, 93, 7033-7038.
61. Weinkam, R. J.; Jorgensen, E. C. Angiotensin II Analogs. IX. Conformational Studies of Angiotensin II by Proton Magnetic Resonance. J. Am. Chem. Soc. 1971, 93, 7038-7044
62. Nikiforovich, G. V.; Vesterman, B. G.; Betins, J. Combined Use of Spectroscopic and Energy Calculation Methods for the Determination of Peptide Conformation in Solution. Biophys. Chem. 1988, 31, 101-106.
63. Nikiforovich, G. V.; Vesterman, B.; Betins, J.; Podins, L. The Space Structure of a Conformationally Labile Oligopeptide in Solution: Angiotensin. J. Biomol. Struct. Dyn. 1987, 4, 1119-1135.
64. Nikiforovich, G. V.; Marshall, G. R. Three-Dimensional Recognition Requirements for Angiotensin Agonists: A Novel Solution for an Old Problem. Biochem. Biophys. Res. Commun. 1993, 195, 222-228.
65. 1H NMR Conformational Studies in Water of Angiotensin-II Analogs Modified at the N - Termini and C-Termini - Interactions of the Aromatic Side-Chains and Folding of the N-Terminal Domain. Collect. Czech. Chem. Commun. 1994, 59, 2523-2532.
66. Tzakos, A.; Bonvin, M. J. J.; Troganis, A.; Cordopatis, P.; Amzel, M.; Gerothanassis, P. I.; van Nuland N. 2003, 270, 849-860.
67. 5 Angiotensin II. Biopolymers 1977, 16, 1929-1943.
68. Greff, D.; Fermandjian, S.; Fromageot, P.; Khosla, M. C.; Smeby, R. R.; Bumpus, F. M. Circular-Dichroism Spectra of Truncated and Other Analogs of Angiotensin II. Eur. J. Biochem. 1976, 61, 297-305.
69. Lintner, K.; Fermandjian, S.; Fromageot, P.; Khosla, M. C.; Smeby, R. R.; Bumpus, F. M. Circular Dichroism Studies of Angiotensin II and Analogues: Effects of Primary Sequence, Solvent, and pH on the Side-Chain Conformation. Biochemistry 1977, 16, 806-812.
70. Turner, R. J.; Matsoukas, J. M.; Moore, G. J. Fluorescence Properties of Angiotensin-II Analogs in Receptor-Simulating Environments - Relationship Between Tyrosinate Fluorescence Lifetime and Biological-Activity. Biochim. Biophys. Acta 1991, 1065, 21-28.
71. Polevaya, L.; Mavromoustakos, T.; Zoumboulakis, P.; Grdadolnik S. G.; Roumelioti, P.; Giatas, N.; Mutule, I.; Keivish, T.; Vlahak D. V.; Iliodromitis, E. K.; Kremastinos, D. T.; Matsoukas, J. Synthesis and Study of a Cyclic Angiotensin II Antagonist Analogue Reveals the Role of Pi*-Pi* Interactions in the C-Terminal Aromatic Residue for Agonist Activity and its Structure Resemblance with AT(1) Non-Peptide Antagonists. Bioorg. Med. Chem. 2001, 9, 1639-1647.
72. Mavromoustakos, T.; Kolocouris, A.; Zervou, M.; Roumelioti, P.; Matsoukas, J.; Weisemann, R. An Effort to Understand the Molecular Basis of Hypertension Through the Study of Conformational Analysis of Losartan and Sarmesin Using a Combination of Nuclear Magnetic Resonance Spectroscopy and Theoretical Calculations. J. Med. Chem. 1999, 42, 1714-1722.
73. 2 Terminal Domain of Angiotensin-II (Ang-II) and [Sar(1)]Angiotensin-II on Conformation and Activity - NMR Evidence for Aromatic Ring Clustering and Peptide Backbone Folding Compared with [Des-1,2,3]Angiotensin-II. J. Biol. Chem. 1994, 269, 5303-5312.
74. 8]AngII in Dimethylsulfoxide by Nuclear Overhauser Effect (NOE) Enhancement Spectroscopy - Cis-Trans Isomerism of the His-Pro Bond. Collect. Czech. Chem. Commun. 1990, 55, 1106-1111.
75. 1]Angiotensin-II Conformation by Nuclear Overhauser Effect Spectroscopy in the Rotating Frame (ROESY) - Clustering of the Aromatic Rings in Dimethylsulfoxide. Peptides 1990, 11, 359-366.
76. Matsoukas, J. M.; Moore, G. J. NMR-Studies on Angiotensin-II - Histidine and Phenylalanine Ring Stacking and Biological-Activity. Biochem. Biophys. Res. Commun. 1984, 122, 434-438.
77. Matsoukas, J. M.; Polevaya, L.; Ancans, J.; Mavromoustakos, T.; Kolocouris, A.; Roumelioti, P.; Vlahakos, D. V.; Yamdagni, R.; Wu, Q.; Moore, G. J. The Design and Synthesis of a Potent Angiotensin II Cyclic Analogue Confirms the Ring Cluster Receptor Conformation of the Hormone Angiotensin II. Bioorg. Med. Chem. 2000, 8, 1-10.
78. 1 Antagonists. Bioorg. Med. Chem. Lett. 2000, 10, 755-758.
79. Matsoukas, J. M.; Agelis, G.; Hondrelis, J.; Yamdagni, R.; Wu, Q.; Ganter, R.; Smith, J. R.; Moore, D.; Moore, G. J. Synthesis and Biological Activities of Angiotensin II, Sarilesin, and Sarmesin Analogues Containing Aze or Pip at Position 7. J. Med. Chem. 1993, 36, 904-911.
80. Porunkevich, E. A.; Ratkevich, M. P.; Kublis, G. G.; Mutulis, F. K.; Chipens, G. I. General Principles of Mast Cell Activation by Cyclic Analogs of Basic Vasoactive Peptides. Biokhimiia 1990, 55, 988-994.
81. Zhang, W. J.; Nikiforovich, G. V.; Perodin, J.; Richard, D. E.; Escher, E.; Marshall, G. R. Novel Cyclic Analogs of Angiotensin II with Cyclization Between Positions 5 and 7: Conformational and Biological Implications. J. Med. Chem. 1996, 39, 2738-2744.
82. Spear, K. L.; Brown, M. S.; Reinhard, E. J.; McMahon, E. G.; Olins, G. M.; Palomo, M. A.; Patton, D. R. Conformational Restriction of Angiotensin II: Cyclic Analogues Having High Potency. J. Med. Chem. 1990, 33, 1935-1940.
83. Nikiforovich, G. V.; Kao, J. L.; Plucinska, K.; Zhang, W. J.; Marshall, G. R. Conformational Analysis of Two Cyclic Analogs of Angiotensin: Implications for the Biologically Active Conformation. Biochemistry 1994, 33, 3591-3598.
84. Plucinska, K.; Kataoka, T.; Yodo, M.; Cody, W. L.; He, J. X.; Humblet, C.; Lu, G. H.; Lunney, E.; Major, T. C.; Panek, R. L. Schelkun, P. ; Skeean, R.; Marshall, G. R. Multiple Binding Modes for the Receptor-Bound Conformations of Cyclic All Agonists. J. Med. Chem. 1993, 36, 1902-1913.
85. Jorgensen, E. C.; Patton, W. Angiotensin II Analogs. II. Cyclo-(-Val-Tyr-Ile-His-Pro-Phe-). J. Med. Chem. 1969, 12, 935-936.
86. Matsoukas, J. M.; Hondrelis, J.; Agelis, G.; Barlos, K.; Gatos, D.; Ganter, R.; Moore, D.; Moore, G. J. Novel Synthesis of Cyclic Amide-Linked Analogues of Angiotensins II and III. J. Med. Chem. 1994, 37, 2958-2969.
87. Schmidt, B.; Lindman, S.; Tong, W.; Lindeberg, G.; Gogoll, A.; Lai, Z.; Thornwall, M.; Synnergren, B.; Nilsson, A.; Welch, C. J.; Sohtell, M.; Westerlund, C.; Nyberg, F.; Karlen, A.; Hallberg, A. Design, Synthesis, and Biological Activities of Four Angiotensin II Receptor Ligands with Gamma-Turn Mimetics Replacing Amino Acid Residues 3-5. J. Med. Chem. 1997, 40, 903-919.
88. Lindman, S.; Lindeberg, G.; Gogoll, A.; Nyberg, F.; Karlen, A.; Hallberg, A. Synthesis, Receptor Binding Affinities and Conformational Properties of Cyclic Methylenedithioether Analogues of Angiotensin II. Bioorg. Med. Chem. 2001, 9, 763-772.;
89. Lindman, S.; Lindeberg, G.; Nyberg, F.; Karlen, A.; Hallberg, A. Comparison of Three Gamma-Turn Mimetic Scaffolds Incorporated into Angiotensin II. Bioorg. Med. Chem. 2000, 8, 2375-2383.
90. Sargent, D. F.; Schwyzer, R. Membrane Lipid Phase as Catalyst for Peptide-Receptor Interactions. Proc. Natl. Acad. Sci. U S. A. 1986, 83, 5774-5778.
91. Surewicz, W. K.; Mantsch, H. H. Effect of Membrane-Binding on the Conformation of Angiotensin-II and its Analogs - A Fourier-Transform Infrared Spectroscopic Study. Biophys. J. 1988, 53, A632-A632.
92. Cho, N. J.; Asher, S. A. UV Resonance Raman and Absorption Studies of Angiotensin II Conformation in Lipid Environments. Biospectroscopy 1996, 2, 71-82.
93. Holtz, J. S. W.; Lednev, I. K.; Asher, S. A. UV Resonance Raman Study of Angiotensin II Conformation in Nonaqueous Environments: Lipid Micelles and Acetonitrile. Biopolymers 2000, 57, 55-63.
94. Carpenter, K. A.; Wilkes, B. C.; Schiller, P. W. The Octapeptide Angiotensin II Adopts a Well-Defined Structure in a Phospholipid Environment. Eur. J Biochem. 1998, 251, 448-53;
95. Wilkes C. B.; Masaro L.; Schiller, P. W.; Carpenter K. A. Angiotensin II vs its Type I Antagonists: Conformational Requirements for Receptor Binding Assessed from NMR and Receptor Docking Experiments. J. Med. Chem. 2002, 45, 4410-4418.
96. 7]Angiotensin III with Dodecylphosphocholine Micelles: NMR and Molecular Dynamics Studies. Magn. Reson. Chem. 1999, 37, 279-286.
97. 7] Angiotensin III by NMR and Molecular Dynamics Methods. Magn. Reson. Chem. 1998, 36, 815-825.
98. Warner, G. T.; Jarvis, B. Olmesartan Medoxomil. Drugs 2002, 62, 1345-1353.
99. Kirch, W., Horn, B.; Schweizer, J. Comparison of Angiotensin II Receptor Antagonists. Eur. J. Clin. Invest. 2001, 31, 698-706.
100. Pierson, M. E.; Freer, R. J. Analysis of the Active Conformation of Angiotensin II: A Comparison of AII and Non-Peptide AII Antagonists. Pept. Res. 1992, 5, 102-105.
101. Wexler, R. R.; Greenlee, W. J.; Irvin, J. D.; Goldberg, M. R.; Prendergast, K.; Smith, R. D.; Timmermans, P. B. Nonpeptide Angiotensin II Receptor Antagonists: The Next Generation in Antihypertensive Therapy. J. Med. Chem. 1996, 39, 625-56.
102. Carini, D. J.; Duncia, J. V.; Aldrich, P. E.; Chiu, A, T.; Johnson, A. L.; Pierce, M. E.; Price, W. A.; Santella, J. B.; 3rd, Wells, G. J., Wexler, R. R.; et al. Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of a Series of N-(Biphenylylmethyl)Imidazoles as Potent, Orally Active Antihypertensives. J. Med. Chem. 1991, 34, 2525-2547.
103. Pierson, M. E.; Freer, R. J. Analysis of the Active Conformation of Angiotensin II: A Comparison of AII And Non-Peptide AII Antagonists. Pept. Res. 1992, 5, 102-105.
104. Milligan, G.; Rees, S. Chimaeric G Alpha Proteins: Their Potential Use in Drug Discovery. Trends Pharmacol. Sci. 1999, 20, 118-124.
105. Pertihnhez, T. A.; Nakaie, C. R.; Paiva, A. C. M.; Schreier, S. Spin-Labeled Extracellular Loop From a Seven-Transmembrane Helix Receptor: Studies in Solution and Interaction with Model Membranes. Biopolymers 1997, 42, 821-829.
106. Caffrey, M. A Lipid's Eye View of Membrane Protein Crystallization in Mesophases. Curr. Opin. Struct. Biol. 2000, 10, 486-497.
107. Garcia, K. C.; Desiderio, S. V.; Ronco, P. M.; Verroust, P. J.; Amzel, L. M. Recognition of Angiotensin-II - Antibodies at Different Levels of An Idiotypic Network are Superimposable. Science 1992, 257, 528-531.
108. Bensoussan, M.; Mitchell, T.; Reilly, T., Timmermans, P. B.; Verroust, P. J.; Ronco, P. M. Immunological Reactivity of Angiotensin-II Receptor Antagonists - Possible Implications for Receptor-Binding Sites. Eur. J. Pharmacol. 1993, 247, 169-175.
109. Murphy, K. P.; Xie, D.; Garcia, K. C.; Amzel, L. M.; Freire, E. Structural Energetics of Peptide Recognition - Angiotensin-II Antibody-Binding. Biophys. J. 1993, 64, A284-A284.
110. Pan, Y.; Yuhasz, S. C.; Amzel, L. M. Antiidiotypic Antibodies - Biological Function and Structural Studies. FASEB J. 1995, 9, 43-49.
111. Garcia, K. C.; Ronco, P. M.; Verroust, P. J.; Brunger, A. T.; Amzel, L. M. 3-Dimensional Structure of an Angiotensin-II Fab Complex at 3 Angstrom - Hormone Recognition by an Antiidiotypic Antibody. Science 1992, 257, 502-507.
112. Smith, R. D.; Timmermans, P. B, Human Angiotensin Receptor Subtypes. Curr. Opin. Nephrol. Hypertens. 1994, 3, 112-122.
113. Bergsma, D. J.; Ellis, C.; Kumar, C.; Nuthulaganti, P.; Kersten, H.; Elshourbagy, N.; Griffin, E.; Stadel, J. M.; Aiyar, N. Cloning and Characterization of a Human Angiotensin II Type 1 Receptor. Biochem. Biophys. Res. Commun. 1992, 183, 989-995.
114. Mukoyama, M.; Nakajima, M.; Horiuchi, M.; Sasamura, H.; Pratt, R. E.; Dzau, V. J. Expression Cloning of Type 2 Angiotensin II Receptor Reveals a Unique Class of Seven-Transmembrane Receptors. J. Biol. Chem. 1993, 268, 24539-24542.
115. Inoue, Y.; Nakamura, N.; Inagami, T. A Review of Mutagenesis Studies of Angiotensin II Type I Receptor, the Three Dimensional Receptor Model in Search of the Agonist and Antagonist Binding Site and the Hypothesis of a Receptor Activation Mechanism. J. Hypertens. 1997, 15, 703-714.
116. 1 Receptor. Trends Pharmacol. Sci. 1996, 17, 135-140.
117. 1 Receptor in Agonist Activation. J. Biol. Chem. 1995, 270, 28511-28514.
118. 1a Angiotensin II Receptor are Involved in the Differential Recognition of Peptide and Nonpeptide Ligands. Biochem. Biophys. Res. Commun. 1995, 209, 153-160.
119. Ohyama, K.; Yamano, Y.; Sano, T.; Nakagomi, Y.; Hamakubo, T.; Morishima, I.; Inagami, T. Disulfide Bridges in Extracellular Domains of Angiotensin II Receptor Type IA. Regul. Pept. 1995, 57, 141-147.
120. 1 Receptor. J. Biol. Chem. 1994, 269, 30953-30959.
121. Noda, K., Saad, Y., Kinoshita, A., Boyle, T. P., Graham, R. M., Husain, A.; Karnik, S. S. Tetrazole and Carboxylate Groups of Angiotensin Receptor Antagonists Bind to the Same Subsite by Different Mechanisms. J. Biol. Chem. 1995, 270, 2284-2289.
122. 1 Subtype, G Protein Coupled Receptor. Chem. Biol. 1994, 1, 211-221.
123. 1). J. Biol. Chem. 1995, 270, 14024-14030.
124. Joseph, M., P.; Maigret, B.; Bonnafous, J. C.; Marie, J.; Scheraga, H. A. A Computer Modeling Postulated Mechanism for Angiotensin II Receptor Activation. J. Protein Chem. 1995, 14, 381-398.
125. Joseph, M. P.; Maigret, B.; Scheraga, H. A. Proposals for the Angiotensin II Receptor-Bound Conformation by Comparative Computer Modeling of AII and Cyclic Analogs. Int. J. Pept. Protein. Res. 1995, 46, 514-526.
126. 1 Receptor: Influence of the Size of the Agonist Switch Binding Residue Asn(111). Biochemistry 1998, 37, 15791-15798.
127. 1a Angiotensin II Receptor is Essential for its Coupling to Phospholipase C. J. Biol. Chem. 1994, 269, 20815-20818.
128. Baldwin, J. M. The Probable Arrangement of the Helices in G Protein-Coupled Receptors. EMBO J. 1993, 12, 1693-1703.
129. Oliveira, L.; Paiva, A. C.; Vriend, G. A Low-Resolution Model for the Interaction of G Proteins with G Protein-Coupled Receptors. Protein. Eng. 1999, 12, 1087-1095.
130. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor. Science 2000, 289, 739-745.
131. Teller, D. C.; Okada, T.; Behnke, C. A.; Palczewski, K.; Stenkamp, R. E. Advances in Determination of a High-Resolution Three-Dimensional Structure of Rhodopsin, a Model of G-Protein-Coupled Receptors (GPCRs). Biochemistry 2001, 40, 7761-7772.
132. Nikiforovich, G. V.; Marshall, G. R. 3D Model for TM Region of the AT-1 Receptor in Complex with Angiotensin II Independently Validated by Site-Directed Mutagenesis Data. Biochem. Biophys. Res. Commun. 2001, 286, 1204-1211.
133. 1 Receptor as a Ligand Contact Point: Receptor-Bound Angiotensin II Adopts an Extended Structure. Biochemistry 2000, 39, 9662-9670.
134. 1) with Photosensitive Analogs of Angiotensin II. Mol. Endocrinol. 1999, 13, 578-586.
135. Schambye, H. T.; Hjorth, S. A.; Bergsma, D. J.; Sathe, G.; Schwartz, T. W. Differentiation Between Binding Sites for Angiotensin-II and Nonpeptide Antagonists on the Angiotensin- II Type 1 Receptors. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 7046-7050.
136. Prendergast, K.; Adams, K.; Greenlee, W. J.; Nachbar, R. B.; Patchett, A. A.; Underwood, J. Derivation of a 3D Pharmacophore Model for the Angiotensin-II Site One 'Receptor. J. Comput.- Aided Mol. Des. 1994, 8, 491-512.;
137. Wexler, R. R.; Greenlee, W. J.; Irvin, J. D.; Goldberg, M. R.; Prendergast, K.; Smith, R. D. and Timmermans, P. B. M. W. M. Nonpeptide Angiotensin II Receptor Antagonists: The Next Generation in Antihypertensive Therapy. J. Med. Chem. 1996, 39, 625-656 and references therein.
138. Kunishima, N.; Shimada, Y.; Tsuji, Y.; Sato, T.; Yamamoto, M.; Kumasaka, T.; Nakanishi, S.; Jingami, H.; Morikawa, K. Structural Basis of Glutamate Recognition by a Dimeric Metabotropic Glutamate Receptor. Nature 2000, 407, 971-977.
139. Okada, T.; Ernst, O. P.; Palczewski, K.; Hofmann, K. P. Activation of Rhodopsin: New Insights from Structural and Biochemical Studies. Trends Biochem. Sci. 2001, 26, 318-324.
140. Valensin, D.; D'Amelio, N.; Gaggelli, E.; Gaggelli, N.; Valensin, G. NMR Studies on the Interaction of Angiotensin II with Fragment Peptides of the Rat Angiotensin II Receptor AT(1a). J. Inorg. Biochem. 2001, 86, 466.
141. 2 Relaxation by Mutual Cancellation of Dipole-Dipole Coupling and Chemical Shift Anisotropy Indicates an Avenue to NMR Structures of Very Large Biological Macromolecules in Solution. Proc. Natl. Acad. Sci. U S. A. 1997, 94, 12366-12371.
142. Smith, S. O.; Bormann, B. J. Determination of Helix-Helix Interactions in Membranes by Rotational Resonance NMR. Proc. Natl. Acad. Sci. USA 1995, 92, 488-491.
143. Wang, J.; Balazs, Y. S.; Thompson, L. K. Solid-state REDOR NMR Distance Measurements at the Ligand Site of a Bacterial Chemotaxis Membrane Receptor. Biochemistry 1997, 36, 1699-703.
144. Hong, M.; Gross, J. D.; Rienstra, C. M.; Griffin, R. G.; Kumashiro, K. K.; Schmidt-Rohr K. Coupling Amplification in 2D MAS NMR and its Application to Torsion Angle Determination in Peptides. J. Mag. Res. 1997, 129, 85-92.
145. Marassi, F. M.; Ma, C.; Gratkowski, H.; Straus, S. K.; Strebel, K.; Oblatt-Montal, M.; Montal, M.; Opella, S. J. Correlation of the Structural and Functional Domains in the Membrane Protein VPU from HIV-1. Proc. Natl. Acad Sci. U. S. A. 1999, 96, 14336-14341.
146. Sanders C. R.; Hare B. J.; Howard K. P.; Prestegard J. H. Magnetically Oriented Phospholipid Micelles as a Tool for the Study of Membrane Associated Molecules. Prog. NMR Spectrosc. 1994, 26, 421-444.
147. Milligan, J. F.; Matteucci, M. D.; Martin, J. C. Current Concepts in Antisense Drug Design. J. Med. Chem. 1993, 36 (14), 1923-1937.
148. Mayer, M.; Meyer, B. Mapping the Active Site of Angiotensin-Converting Enzyme by Transferred NOE Spectroscopy. J. Med. Chem. 2000, 43, 2093-2099.
149. Kurup, A.; Garg, R.; Hansch, C. Comparative QSAR Study of Tyrosine Kinase Inhibitors. Chem. Rev. 2001, 101, 2573-2600.
150. Vedani, A.; Dobler, M. 5D-QSAR: The Key for Simulating Induced Fit? J. Med. Chem. 2002, 45, 2139-2149.